IRIS UniCatt

Armuzzi, Alessandro
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.703
EU - Europa 8.490
AS - Asia 7.129
SA - Sud America 1.392
AF - Africa 191
OC - Oceania 27
Continente sconosciuto - Info sul continente non disponibili 18
AN - Antartide 1
Totale 25.951
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.455
DE - Germania 3.704
SG - Singapore 3.416
CN - Cina 1.664
SE - Svezia 1.168
BR - Brasile 1.145
IT - Italia 868
FR - Francia 635
VN - Vietnam 547
UA - Ucraina 529
GB - Regno Unito 355
IE - Irlanda 346
IN - India 280
FI - Finlandia 234
ID - Indonesia 223
JP - Giappone 201
RU - Federazione Russa 179
TR - Turchia 168
HK - Hong Kong 133
PL - Polonia 114
AR - Argentina 113
CA - Canada 105
BD - Bangladesh 91
MX - Messico 86
IQ - Iraq 66
NL - Olanda 58
KR - Corea 54
ES - Italia 51
AT - Austria 48
ZA - Sudafrica 45
BE - Belgio 40
SA - Arabia Saudita 33
EC - Ecuador 32
IR - Iran 30
PK - Pakistan 30
CO - Colombia 26
AU - Australia 25
CZ - Repubblica Ceca 24
VE - Venezuela 24
MA - Marocco 23
CI - Costa d'Avorio 21
EG - Egitto 21
UZ - Uzbekistan 21
LT - Lituania 20
TN - Tunisia 20
JO - Giordania 19
CH - Svizzera 18
PH - Filippine 18
IL - Israele 16
KE - Kenya 16
PT - Portogallo 16
EU - Europa 15
AZ - Azerbaigian 13
HU - Ungheria 13
JM - Giamaica 13
NP - Nepal 13
RO - Romania 13
AE - Emirati Arabi Uniti 12
PE - Perù 12
UY - Uruguay 12
CL - Cile 11
ET - Etiopia 11
DZ - Algeria 10
KZ - Kazakistan 10
CR - Costa Rica 9
OM - Oman 9
PY - Paraguay 9
AL - Albania 8
BG - Bulgaria 8
HN - Honduras 7
BH - Bahrain 6
LV - Lettonia 6
RS - Serbia 6
TT - Trinidad e Tobago 6
BO - Bolivia 5
MY - Malesia 5
NI - Nicaragua 5
AO - Angola 4
BY - Bielorussia 4
BZ - Belize 4
GR - Grecia 4
KG - Kirghizistan 4
KH - Cambogia 4
LB - Libano 4
MM - Myanmar 4
MO - Macao, regione amministrativa speciale della Cina 4
PA - Panama 4
SN - Senegal 4
TH - Thailandia 4
TW - Taiwan 4
BN - Brunei Darussalam 3
CG - Congo 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
EE - Estonia 3
HR - Croazia 3
LK - Sri Lanka 3
NG - Nigeria 3
PS - Palestinian Territory 3
QA - Qatar 3
Totale 25.903
Salva come PNG Salva come JPEG
Città #
Singapore 1.970
Chandler 1.277
Cologne 1.211
Ashburn 878
San Jose 828
Beijing 375
Dublin 336
Jacksonville 325
San Mateo 264
New York 256
Los Angeles 226
Lauterbourg 205
Jakarta 204
Ho Chi Minh City 183
Tokyo 182
Hefei 181
Milan 174
Nanjing 172
Munich 160
Ann Arbor 150
Wilmington 144
Boston 138
Dearborn 134
Hanoi 124
Cattolica 123
Chicago 122
Nürnberg 119
The Dalles 117
Hong Kong 115
Rome 114
Frankfurt am Main 108
Princeton 107
Izmir 103
São Paulo 103
Marseille 85
Houston 82
Moscow 78
Helsinki 71
Seattle 67
Dallas 66
Bremen 62
Essen 61
Santa Clara 61
Nanchang 60
Woodbridge 59
Lawrence 57
Warsaw 56
Redwood City 53
Council Bluffs 52
Buffalo 51
Lancaster 47
Seoul 47
Hangzhou 45
Fairfield 44
Pune 44
Kent 42
Boardman 41
Norwalk 38
Turku 37
Brussels 36
Rio de Janeiro 36
Kraków 35
Mountain View 35
Paris 35
Brooklyn 34
Hebei 34
Shanghai 34
Belo Horizonte 33
Hyderabad 33
Nuremberg 33
Tianjin 33
St Louis 32
Amsterdam 31
Da Nang 31
Guangzhou 31
Shenyang 31
Baghdad 30
London 29
Mexico City 29
Stockholm 29
Chennai 28
Denver 28
Montreal 28
Toronto 28
Johannesburg 27
Augusta 26
Jiaxing 26
Lappeenranta 26
University Park 26
Atlanta 25
Changsha 25
Orem 25
Detroit 24
Düsseldorf 24
Kunming 24
Leawood 23
Haiphong 22
Abidjan 21
Brasília 21
San Francisco 20
Totale 13.815
Salva come PNG Salva come JPEG
Nome #
3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 1: Diagnosis and medical management 1.355
A) Prevalence of the K469E polymorphism of intercellular adhesion molecule 1 gene in Italian patients with inflammatory bowel disease. 367
A) Infliximab in the treatment of steroid-dependent ulcerative colitis. 316
Asthma in patients admitted to emergency department for COVID-19: prevalence and risk of hospitalization 309
A) Lack of endoscopic visualization of intestinal villi with the "immersion technique" in overt atrophic celiac disease 264
Growth hormone in inflammatory bowel disease 260
13C-methionine breath tests for mitochondrial liver function assessment. 260
13C-breath tests in the study of microsomal liver function 242
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 232
Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study 228
Sacroileitis and peripheral arthropathy associated with ulcerative colitis: effect of infliximab on both articular and intestinal symptoms 226
Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study 219
134C-breath tests in the study of mitochondrial liver function 217
FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents 209
Personalized Clinical Phenotyping through Systems Medicine and Artificial Intelligence 209
The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease 207
13C-breath tests in the study of microsomial liver function 200
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission. 197
13C-methionine breath tests for mitochondrial liver function assessment 192
Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study 190
Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients. 189
Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: Effects of combined therapy with immunosuppressants. 188
A) Advances in extracorporeal detoxification by MARS dialysis in patients with liver failure 175
Development of psoriasis scalp with alopecia during treatment of Crohn's disease with infliximab and rapid response to both diseases to ustekinumab 174
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 171
Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents 169
Delta13CO2 excretion and expression of dyspeptic symptoms in patients evaluated for Helicobacter pylori infection by [13C] urea breath test 168
Helicobacter pylori infection affects eosinophilic cationic protein in the gastric juice of patients with idiopathic chronic urticaria 168
ag) Fecal calprotectin in first-degree relatives of patients with ulcerative colitis. 167
[Helicobacter pylori and gastric carcinoma] 166
Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. 166
13C-breath tests in the study of mitochondrial liver function 165
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 163
Association between K469E allele of intercellular adhesion molecule 1 gene and inflammatory bowel disease in different populations. 163
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 163
Fecal calprotectin in first-degree relatives of patients with ulcerative colitis 162
Ileal Crohn's disease: CEUS determination of activity 161
-Can 13C urea breath test predict resistance to therapy in Helicobacter pylori infection? 160
A) Study of liver function in healthy elderly subjects using the 13C-methacetin breath test 158
Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study 157
Challenges in crohn’s disease management after gastrointestinal cancer diagnosis 157
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy 155
Levofloxacin based regimens for the eradication of Helicobacter pylori 153
Magnesium Absorption in Intestinal Cells: Evidence of Cross-Talk between EGF and TRPM6 and Novel Implications for Cetuximab Therapy 152
Anti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery? 151
Helicobacter pylori treatment: a role for probiotics? 149
Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab 148
A) Antibodies to Saccharomyces cerevisiae: are they useful in clinical practice? 146
The role of inflammatory bowel disease nurses for patients on biologic therapy during the COVID-19 pandemic 143
Probiotics and Helicobacter pylori eradication 142
Efficacy and tolerability of antibiotics in patients undergoing H. pylori eradication 141
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 140
Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year. 140
Helicobacter pylori CagA-positive strains affect oxygen free radicals generation by gastric mucosa 139
Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease. 138
A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: infliximab and surgery 138
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy 138
A novel pathogenic role for microvasculature in inflammatory bowel disease. 137
Infliximab in Crohn's disease: early and long-term treatment. 136
Case report: Dupilumab treatment improved type 2 disorders in a patient with IPEX syndrome diagnosis 134
Signs of dissociation and symptoms of post-traumatic stress disorder in inflammatory bowel disease. A case-control study 134
Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases 133
Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update 131
13C-methacetin breath test for monitoring hepatic function in cirrhotic patients before and after liver transplantation. 131
Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis 131
Biological therapies for inflammatory bowel disease: research drives clinics. 130
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 130
Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. 129
Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease 129
Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases 128
Management of perianal fistulas in Crohn's disease: an up-to-date review 127
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 127
Exploring the link: Porto-sinusoidal vascular disorder and inflammatory bowel disease - A comprehensive narrative review 126
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 126
A) Quantitative evaluation of liver function by the methionine and aminopyrine breath tests in the early stages of liver transplantation 124
Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders 124
What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients? 123
Gender affects 13C-ketoisocaproic acid breath test 122
Paradoxical arthritis occurring during anti-TNF in patients with Inflammatory Bowel Disease: histological and immunological features of a complex synovitis. 121
Characterization of Sarcopenia in an IBD Population Attending an Italian Gastroenterology Tertiary Center 121
Multiparametric Evaluation Predicts Different Mid-Term Outcomes in Crohn's Disease 121
Serial Fecal Microbiota Infusions via Colonoscopy for Active Ulcerative Colitis: A Feasibility, Safety, and Translational Monocentric Italian Study 119
Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease 119
Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test. 118
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study. 118
Challenges in Crohn's Disease Management after Gastrointestinal Cancer Diagnosis 117
Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. 117
Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test 116
A transition clinic model for inflammatory bowel disease between two tertiary care centers: outcomes and predictive factors 116
Epidemiology of inflammatory bowel disease in the Republic of San Marino: The “EPIMICI – San Marino” study 115
Review article: breath testing for human liver function assessment. 113
Transition of inflammatory bowel disease patients from pediatric to adult care: an observational study on a joint-visits approach 113
Histologic Disease Persists beyond Mucosal Healing and Could Predict Reactivation in Ulcerative Colitis 113
Radiomics could predict surgery at 10 years in Crohn's disease 112
Saccharomyces cerevisiae-associated diarrhea in an immunocompetent patient with ulcerative colitis 112
-Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation 112
Therapeutic drug monitoring is more cost-effective than a clinically-based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multi-centre study. 111
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial 111
The awareness of the IBD nurse position among patients from an Italian tertiary IBD centre 111
Mucosal healing in ulcerative colitis: surveillance or colectomy? 110
Totale 16.970
Salva come PNG Salva come JPEG
Categoria #
all - tutte 101.523
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 101.523
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021265 0 0 0 0 0 0 0 0 0 0 242 23
2021/20221.510 97 120 28 178 43 48 23 246 45 94 269 319
2022/20233.459 421 441 239 540 266 394 163 302 413 98 117 65
2023/20243.061 79 490 61 108 88 270 95 1.196 214 81 179 200
2024/20253.565 67 107 304 82 285 146 181 183 498 378 741 593
2025/20268.930 1.500 305 572 1.065 1.688 449 1.605 470 632 631 13 0
Totale 26.261